Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
26 Settembre 2023 - 1:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that Dr. Louis J. Aronne, Founder and
Director of the Center for Weight Management at Weill-Cornell
Medical Center, and a leading authority in obesity, will present
the results of its 24-week clinical trial of pemvidutide in the
treatment of subjects with overweight or obesity in an oral
presentation at the 59th Annual Meeting of the European Association
for the Study of Diabetes in Hamburg, Germany. Pemvidutide is a
novel, investigational, peptide-based GLP-1/glucagon dual receptor
agonist in development for the treatment of obesity and
non-alcoholic steatohepatitis (NASH).
Details for the oral presentation are as
follows:
Title: |
Phase 2, Randomized, Placebo-controlled Trial of pemvidutide, a
GLP-1/glucagon dual receptor agonist, in subjects with overweight
or obesity: a 24-week interim analysis (Session OP 10, Oral
Presentation 60) |
Presenter: |
Louis J. Aronne, M.D., Founder and Director, Center for Weight
Management at Weill-Cornell Medical Center |
Date/Time: |
Tuesday, October 3, 2023, at 4:30 pm CEST |
About Pemvidutide
Pemvidutide is a novel, investigational,
peptide-based GLP-1/glucagon dual receptor agonist in development
for the treatment of obesity and NASH. Activation of the GLP-1 and
glucagon receptors is believed to mimic the complementary effects
of diet and exercise on weight loss, with GLP-1 suppressing
appetite and glucagon increasing energy expenditure. Glucagon is
also recognized as having direct effects on hepatic fat metabolism,
leading to rapid reductions in levels of liver fat. Pemvidutide
incorporates the EuPort™ domain, a proprietary technology that
increases its serum half-life for weekly dosing while likely
slowing the entry of pemvidutide into the bloodstream, which may
improve its tolerability.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical
company focused on developing innovative next-generation
therapeutics for the treatment of patients with liver diseases and
obesity. The Company’s lead product candidate, pemvidutide, is a
GLP-1/glucagon dual receptor agonist that is being developed for
the treatment of obesity and NASH. In addition, Altimmune is
developing HepTcell™, an immunotherapeutic designed to achieve a
functional cure for chronic hepatitis B. For more information,
please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor & Media Contacts:
Richard EisenstadtChief Financial OfficerPhone:
240-654-1450reisenstadt@altimmune.com
Grafico Azioni Altimmune (NASDAQ:ALT)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Altimmune (NASDAQ:ALT)
Storico
Da Mag 2023 a Mag 2024